BCI
MRVI icon

Brinker Capital Investments’s Maravai LifeSciences MRVI Stock Holding History

Brinker Capital Investments’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$607K Buy
97,236
+85,909
+758% +$371K ﹤0.01% 1392
2026
Q1 		$32.1K Buy
+11,327
New +$38.4K ﹤0.01% 1924
2025
Q3 		– Sell
-321,879
Closed -$776K – 2101
2025
Q2 		$776K Buy
321,879
+82,522
+34% +$173K 0.01% 1326
2025
Q1 		$529K Buy
239,357
+142,665
+148% +$564K 0.01% 1398
2024
Q4 		$527K Sell
96,692
-39,057
-29% -$251K 0.01% 1332
2024
Q3 		$1.13M Buy
135,749
+6,177
+5% +$53.4K 0.01% 990
2024
Q2 		$928K Buy
129,572
+14,333
+12% +$124K 0.01% 1026
2024
Q1 		$999K Buy
115,239
+14,519
+14% +$98.2K 0.01% 983
2023
Q4 		$692K Buy
100,720
+35,564
+55% +$230K 0.01% 1091
2023
Q3 		$652K Buy
65,156
+11,564
+22% +$127K 0.01% 1100
2023
Q2 		$666K Buy
53,592
+22,833
+74% +$308K 0.01% 1104
2023
Q1 		$431K Buy
30,759
+15,690
+104% +$225K 0.01% 1191
2022
Q4 		$216K Buy
+15,069
New +$237K ﹤0.01% 1273
2022
Q3 		– Sell
-15,520
Closed -$441K – 1373
2022
Q2 		$441K Buy
+15,520
New +$492K 0.01% 1023

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Brinker Capital Investments's MRVI Position: Q2 2026 in Review

Brinker Capital Investments increased its Maravai LifeSciences (MRVI) stake by 758% in Q2 2026, buying an estimated $371K and bringing the position to 97,236 shares worth $607K. The position accounts for ﹤0.01% of the portfolio, ranked #1392.

Brinker Capital Investments first reported a position in MRVI in Q2 2022 and has held it in 14 quarters since. The position peaked at $1.13M in Q3 2024. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Brinker Capital Investments held 97,236 shares of Maravai LifeSciences worth $607K as of Q2 2026.
  • Brinker Capital Investments bought 85,909 Maravai LifeSciences shares in Q2 2026, an estimated $371K.
  • Maravai LifeSciences made up ﹤0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #1392 holding.
  • Brinker Capital Investments first reported a position in Maravai LifeSciences in Q2 2022 and has held it in 14 quarters since.
  • Brinker Capital Investments's Maravai LifeSciences position peaked at $1.13M in Q3 2024.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.